NASDAQ · INCY
Incyte Corporation
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
Loading market information…
OTC · REPCF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
RepliCel Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow RepliCel Life Sciences Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
RepliCel Life Sciences Inc., a biotechnology firm based in Vancouver, Canada, specializes in regenerative medicine. The company focuses on developing patient-specific cell therapies designed to address functional cellular deficits. Their treatment methodology involves extracting an individual's own cells from harvested bodily tissues and then cultivating them further in a controlled laboratory environment. RepliCel's pipeline includes several therapeutic candidates: RCT-01, which targets chronic tendinosis; RCS-01, developed for the treatment of aging and sun-damaged skin; and RCH-01, aimed at alleviating hair loss. They are also advancing RCI-02, an innovative device for dermal injections. The company has established key partnerships, including a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to set up clinical research programs for the development and commercialization of RCS-01 and RCT-01. A similar arrangement exists with Shiseido Company, Limited for the clinical research program related to RCH-01. Additionally, RepliCel is engaged in a joint research project with the University of British Columbia to compile a comprehensive hair follicle cell data map.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$116.80-$0.07 (-0.06%)
Incyte Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.92% below the high.
$66.20-$0.08 (-0.12%)
Exelixis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.95% below the high.
$17.39+$1.33 (+8.28%)
Replimune Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.19% below the high.
$1.50-$0.10 (-6.25%)
CEL-SCI Corporation’s quoted price sits in the lower half of its reported 52-week range, 80.77% below the high.
CA$0.08+CA$0.01 (+6.67%)
Resverlogix Corp.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
$2.04-$0.06 (-2.86%)
Jaguar Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$0.01$0.00 (0.0%)
Sirona Biochem Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.85% below the high.
$0.00$0.00 (0.0%)
ProtoKinetix, Incorporated’s quoted price sits in the lower half of its reported 52-week range, 97.58% below the high.
